Advanced or Metastatic Solid Tumors Clinical Trials

18 recruiting

Advanced or Metastatic Solid Tumors Trials at a Glance

37 actively recruiting trials for advanced or metastatic solid tumors are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 1 with 36 trials, with the heaviest enrollment activity in Fairfax, Nashville, and San Antonio. Lead sponsors running advanced or metastatic solid tumors studies include Hanmi Pharmaceutical Company Limited, Chinese PLA General Hospital, and Avistone Biotechnology Co., Ltd..

Browse advanced or metastatic solid tumors trials by phase

Treatments under study

About Advanced or Metastatic Solid Tumors Clinical Trials

Looking for clinical trials for Advanced or Metastatic Solid Tumors? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced or Metastatic Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced or Metastatic Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 37 trials

Recruiting
Phase 1

A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion
Shouyao Holdings (Beijing) Co. LTD122 enrolled1 locationNCT07469982
Recruiting
Phase 1

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

Advanced or Metastatic Solid Tumors
Kangabio AUSTRALIA LTD PTY57 enrolled3 locationsNCT07260305
Recruiting
Phase 1Phase 2

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.63 enrolled15 locationsNCT06307795
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Locally Advanced or Metastatic Solid TumorsNSCLC (Non-small Cell Lung Cancer)Esophageal Squamous Cell Cancer+1 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1Phase 2

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Advanced or Metastatic Solid Tumors
Beijing Biotech60 enrolled1 locationNCT07510828
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.189 enrolled13 locationsNCT06248411
Recruiting
Phase 1

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.96 enrolled5 locationsNCT06716138
Recruiting
Phase 1

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited245 enrolled10 locationsNCT06234397
Recruiting
Phase 1

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Advanced or Metastatic Solid Tumors
Incendia Therapeutics270 enrolled11 locationsNCT05753722
Recruiting
Phase 1

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors
ArriVent BioPharma, Inc.405 enrolled15 locationsNCT07066657
Recruiting
Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled27 locationsNCT07094113
Recruiting
Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast CancerOvarian CancerEndometrial Cancer+2 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1Phase 2

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.250 enrolled3 locationsNCT06974812
Recruiting
Phase 1

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors
Innate Pharma145 enrolled7 locationsNCT06781983
Recruiting
Phase 1

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309

Advanced or Metastatic Solid Tumors
PharmAbcine67 enrolled4 locationsNCT05957081
Recruiting
Phase 1

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited292 enrolled7 locationsNCT06724016
Recruiting
Phase 2

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686